Key Takeaways
- Resilient top line, transient cost pain: Revenue grew 9% YoY on volume, but EBITDA and PAT (INR 4 crore) were hit by fire-related tolling costs, Neogen Ionics ramp-up, and higher interest.
- The battery chemicals thesis is intact and derisked: The Morita JV closed, Pakhajan is on track, and Dahej replacement commissioning is set for Q1 FY27, with INR 400–500 crore FY27 guidance reiterated and Pakhajan salt sales kept as a deliberate buffer.
- Customer approvals are the gating item, and they are imminent: Management expects site audits to begin from March 2026, with several large international customers finalizing approvals shortly, paving the way for bulk consignments in H1 FY27.
- A wall of capital is arriving to clean up the balance sheet: Around INR 550 crore in combined inflows from insurance, the Morita investment, and a promoter preferential issue is expected by Q1 FY27, earmarked for capex completion and working capital reduction.
- What to watch next quarter: The pace of customer site visits and audit outcomes, the actual receipt of the INR 60 crore insurance tranche and Morita funds, and any further clarity on the ramp-up profiles of US and Indian battery cell customers.
Battery Chemicals: Capacity, Approvals & the Non-FEOC Opportunity
- Dahej rebuild on track: The replacement plant is set for partial availability by March-April 2026 and full commissioning by end of June 2026, with stable production expected from Q2 FY27. The team incorporated design improvements from Morita training into the additive production part.
- Pakhajan progressing to schedule: Equipment is on site and assembly is underway; trial production is expected shortly. Electrolyte commercial production is targeted for H1 FY27, with electrolyte salts in H2 FY27.
- Customer approval cycle entering final stage: Management completed modifications by mid-Feb 2026; customers will decide their visit timing within one to three weeks. Several large-scale international customers are expected to finalize approvals shortly, with site audits planned for March, April, and May 2026.
- US customer ramp-up is a spectrum, not a switch: Some customers started working two years back and will scale gradually (Q2 some quantity, then Q3, then Q4); some are price-sensitive and will switch only in Q4 when regulation bites; some previously insisted on Pakhajan only but are now considering Dahej.
- The non-FEOC window is real and time-bound: Batteries made in 2027 cannot use Chinese material, and electrolyte salt shelf life is not more than six months, so stockpiling is not a workaround. By end of December 2026, 12 giga of installed Indian cell capacity is expected, entering 2027 with additions from Reliance, Amara Raja, and Tata.
- India's only non-FEOC compliant electrolyte salt plant: The Morita JV offers a proven-technology strategic alternative to the Chinese supply chain, with Neogen holding an 80% majority stake and supported by a $20 million partner investment.
Dr. Harin Kanani: "We are currently seeing significant tailwinds from the US 45X tax credits non-FEOC requirements and recent price volatility in China, both of which enhance our appeal as a strategic global partner."
Financial Position: Inflows, Costs & the Balance Sheet
- A material liquidity event is approaching: Around INR 550 crore in total expected inflows (insurance, Morita investment, promoter preferential issue) is due either this financial year or in Q1 FY27. The promoter group intends to invest INR 150 crore before March 2026, subject to regulatory guidance on a family trust cooling-off period.
- Insurance recovery is progressing in tranches: A second interim payment of INR 60 crore against rebuilding is ready for issuance. The main stock claim of INR 150–170 crore is expected before end of March 2026, with the full insurance process hopefully completed by September to December 2026.
- Toll manufacturing costs are a bridge, not a permanent drag: Higher costs from interim tolling arrangements will reduce when Dahej comes online, partially replaced by additional power and fuel at Dahej, resulting in a net improvement in the cost structure. Management declined to quantify the current tolling share, calling it need-based across several sites.
- Working capital elevated but in line with growth: The increase in receivables tracks business growth; debtor days typically range from 60 to 90 depending on the international versus domestic sales mix.
- Fund utilization is earmarked for deleveraging and capex: Incoming funds will partly complete capital projects and partly reduce working capital debt. For Dahej loans, the first principal repayment falls in Q1 FY28; for Pakhajan, H1 FY28, each one year from SCOD.
Segment Performance: Inorganic Surge, Organic Steady, CDMO Waiting
- Inorganic chemicals grew 35% YoY, reflecting stronger momentum, though the ex-Neogen Ionics inorganic segment saw a downward trend solely attributed to lower lithium prices. The recent lithium price spike from November/December 2025 will impact Q4 a little and more next year if sustained.
- Organic chemicals grew 6% YoY, with volume growth difficult to quantify because the product mix changes significantly.
- CDMO/Advanced Intermediates held flat YoY despite the Dahej outage: Production was maintained from Mahape and Karakhadi. One semiconductor customer had enough inventory, so that business was skipped this year. Repeat orders and new projects that were on hold are expected to start coming in after customer visits from March 2026.
- Salt business saw a value-wise significant QoQ increase, driven by strong interest from regular larger customers and non-regular one-time buyers.
- Bromine price strength has limited impact because most bromine is contracted for longer periods and contracts with customers also exist; only a two-to-three-times price increase would change the dynamic.
Competitive Moat & Customer Dynamics
- Neogen's USP rests on four pillars: being already ready with three to four years of lab and commercial supply experience; the Mitsubishi collaboration guaranteeing electrolyte quality; backward integration; and actual available capacity.
- Customer restructuring is expanding the market, not shrinking it: Management stated they are not affected by GM/Ford JV changes and that the market has actually expanded with JVs, as more customers are interested compared to earlier.
- One large potential Indian customer rumor was deflected: Asked about news that a major potential customer had put battery plans on the back burner due to lack of Chinese know-how, management said they had received no such communication and discussions continue.
- Customer behavior varies widely: Some are regulatory-driven, some cautious and scaling gradually, some price-sensitive and waiting for Q4. One customer who was more regulatory-driven is among those changing stance, now considering Dahej after previously insisting on Pakhajan only.
Dr. Harin Kanani: "I think one is we are already ready. We already have three-four years experience to make it in the lab and supply successfully and last one or two years even from a commercial plant in Dahej. Second, we have Mitsubishi collaboration. Mitsubishi is known to be the best electrolyte producer in terms of quality. So, then you can be 100% sure about the quality of the supply. And the third is we have the backward integration. Fourth is we have actual capacity because one of the thing is you need to have the capacity."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dahej replacement plant commissioning | Fully compliant and optimized facility; partial availability March-April 2026, full by end of June 2026; stable production from Q2 FY27 | Q1 FY27 |
| Pakhajan commercial production | Electrolyte in H1 FY27; electrolyte salts in H2 FY27; trial salt production by Q2 FY27 (September 2026) | H1/H2 FY27 |
| Dahej site audit and approval | Site audited and approved; most capacity online; good salt-related revenues from Q2, Q3, Q4 | By June 2026 |
| FY27 battery chemicals revenue | INR 400 to INR 500 crore; Pakhajan Q4 salt sales not considered, kept as buffer | FY27 |
| Base business (organic/inorganic) FY27 | Double-digit revenue growth expected with Dahej plant coming on track post-fire | FY27 |
| Insurance second interim payment | INR 60 crore against rebuilding | Within the week |
| Insurance main stock claim | INR 150–170 crore | Before end of March 2026 |
| Morita investment receipt | $20 million from JV partner | End of current quarter or possibly April 2026; by Q1 FY27 |
| Promoter preferential issue | INR 150 crore equity infusion | Before end of March 2026, subject to regulatory approval; worst case Q1 FY27 |
| Total expected inflows | Around INR 550 crore (insurance + Morita + promoter) | Either this year or Q1 FY27 |
| Debt principal repayment start | Dahej: Q1 FY28; Pakhajan: H1 FY28 (one year from SCOD) | FY28 |
| Insurance process completion | Full recovery ultimately achieved | September to December 2026 |
| Capacity utilization ceiling | Salt at 80%; electrolyte up to 100% | Steady-state |
Dr. Harin Kanani: "I am a little bit more careful. What we have done is that Q4 whatever Pakhajan salt sales we have not considered, if Dahej is slightly delayed or electrolyte is delayed, the Q4 salt sales will allow me to make up for that so that we do not go wrong on our guidance in the next financial year."
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated revenue | ₹220 cr, 9% YoY growth |
| Gross profit growth | 13% YoY, with around 150 bps margin expansion |
| Organic chemical revenue | ₹187 cr, 6% YoY growth |
| Inorganic chemical revenue | ₹33 cr, 35% YoY growth |
| Neogen Ionics revenue contribution | ₹12 cr |
| EBITDA | ₹32 cr |
| Profit after tax | ₹4 cr |
| Net debt (standalone) | ₹680 cr |
| Net debt (consolidated) | ₹1,175 cr |
| Insurance claims received (9M FY26) | ₹83.48 cr |
| Net insurance claim receivable | ₹251.12 cr |
| FY27 battery chemicals revenue guidance | ₹400–500 cr, management confirmed no change |
| Dahej replacement plant commissioning timeline | Q1 FY27 |
| Dahej salt capacity addition (1,100 tons) timeline | March 2026, slipped from December 2025 |
| Pakhajan electrolyte commercial production timeline | H1 FY27 |
| Pakhajan electrolyte salt commercial production timeline | H2 FY27 |
| Promoter preferential issue approved | Up to ₹150 cr, subject to regulatory approvals |
| Promoter stake | 51.22% |
| Morita investment in JV | $20 mn for 20% stake; Neogen holds 80% |
| Expected total inflows by Q1 FY27 (insurance, Morita, promoter) | ~₹550 cr |
| India battery cell capacity expected online in current calendar year | ~12 GWh from Ola, Exide, Waaree Energy |
| India battery cell capacity estimate by end of 2027 | 40–50 GWh-plus entering 2028, if everything goes well |
| Neogen electrolyte capacity | 30 GWh worth of capacity ready |
| Total salt capacity at Pakhajan | 5,500 tons; at 80% utilization, ~4,400 tons at $20-plus average price implies ₹1,000 cr-plus revenue potential |
| Pakhajan electrolyte capacity | 30,000 MT annual, three lines, ~2,500 tons monthly |
| Salt capacity utilization ceiling | 80% |
| Electrolyte capacity utilization ceiling | Up to 100% |
| Current revenue run rate | ₹800 cr-plus |
| Expected quarterly run rate in FY27 | ₹225–250 cr |
| Expected FY27 revenue | ~₹950 cr |